tamsulosin and Bladder, Overactive
tamsulosin has been researched along with Bladder, Overactive in 64 studies
Research
Studies (64)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 22 (34.38) | 29.6817 |
2010's | 29 (45.31) | 24.3611 |
2020's | 13 (20.31) | 2.80 |
Authors
Authors | Studies |
---|---|
Fujita, H; Imai, S; Imai, Y; Kamo, I; Kohara, Y; Kuno, H; Nagabukuro, H; Okabe, Y; Saikawa, R; Sakauchi, N; Sato, A; Suzaki, T; Yoshida, M | 1 |
Jong, JJ; Kakizaki, H; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O | 1 |
Cambronero Santos, J; Chapple, C; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT; Schermer, CR; Staskin, D | 1 |
Sahin, A; Urkmez, A; Yildirim, C; Yuksel, OH | 1 |
Chen, Z; Gao, Y; Liang, L; Lin, J; Liu, L; Su, S | 1 |
Peyronnet, B | 1 |
El-Abd, AS; El-Abd, SA; Radwan, MH; Soliman, MG; Tawfik, AM | 1 |
Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O | 1 |
Cambronero Santos, J; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT | 1 |
Kakizaki, H; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O | 1 |
Brucker, B; Bschleipfer, T; Cornu, JN; De Nunzio, C; Drake, MJ; Fusco, F; Gravas, S; Madersbacher, S; Oelke, M; Peyronnet, B; Tutolo, M; van Koeveringe, G | 1 |
Burgio, KL; Falk, K; Goode, PS; Hammontree, L; Johnson, TM; Markland, AD; McGwin, G; Ouslander, JG; Vaughan, CP | 1 |
Asakura, H; Seki, N; Tokunaga, S; Yamanishi, T | 3 |
Behera, DP; Gupta, S; Singh, I; T K, A | 1 |
Krivoborodov, GG; Tur, EI | 1 |
Gainullina, Y; Kosilov, K; Kosilova, L; Kuzina, I; Kuznetsov, V; Loparev, S; Prokofyeva, A | 1 |
Apostolidis, A; Papathanasiou, A; Sakalis, V; Salpiggidis, G; Sfiggas, V; Vouros, I | 1 |
De Wachter, S; Foley, S; Huang, M; Rees, J; Rosa Arias, J; Skoumal, R; Walters, C; Yavuz, Y | 1 |
Gotoh, M; Masumori, N; Nishizawa, O; Takahashi, S; Takeda, M; Yoshida, M | 1 |
Byun, SS; Kim, KH; Lee, JY; Lee, SH; Lee, SJ | 1 |
Gao, ZW; Li, HB; Ren, XQ; Shang, YF; Shao, CS; Xiao, F; Xin, SY; Zhang, JG; Zhang, W | 1 |
Li, J; Liu, B; Wang, Y; Wu, Y | 1 |
Chapple, C; Drake, MJ; Drogendijk, T; Klaver, M; Oelke, M; Sokol, R; Traudtner, K; Van Kerrebroeck, P | 1 |
Ivanovskaya, M; Kosilov, K; Kosilova, L; Loparev, S | 1 |
Doo, SW; Kim, JH; Lee, SW; Yang, HJ; Yang, WJ; Yun, JH | 1 |
Fukuta, F; Ichihara, K; Iwasawa, A; Masumori, N; Tanaka, Y; Tsukamoto, T | 1 |
Chung, BH; Hong, S; Kim, CS; Kim, DK; Kim, JC; Lee, JG; Lee, KS; Lee, YS; Park, CH; Park, JK | 1 |
Chung, BH; Hong, SJ; Kim, CS; Kim, DK; Kim, JC; Lee, HN; Lee, JG; Lee, KS; Park, CH; Park, JK | 1 |
Bae, SR; Cho, SY; Han, CH; Hur, KJ; Kim, HW; Kim, SH; Lee, KW; Lee, YS; Park, BH | 1 |
Ito, N; Kamiyama, Y; Kanamaru, S; Kawakita, M; Matsumoto, K; Muguruma, K; Shirahase, T; Takahashi, T; Tsukazaki, H; Tsunemori, H; Utsunomiya, N | 1 |
Hashizume, K; Iuchi, H; Kakizaki, H; Kita, M; Matsumoto, S; Wada, N | 1 |
Choi, IS; Park, JK; Shin, YS; You, JH; Zhang, LT; Zhao, C | 1 |
Kosilov, K; Kuzina, I; Lobodenko, A; Loparev, S; Shakirova, O; Zhuravskaya, N | 1 |
Bavendam, T; Carlsson, M; Chancellor, M; Guan, Z; Kaplan, SA; Roehrborn, CG | 1 |
Porru, D | 1 |
Bavendam, T; Guan, Z; Jones, JS; Kaplan, SA; Roehrborn, CG; Wang, JT | 1 |
Wyndaele, JJ | 1 |
Matsumoto, S; Uemura, H | 1 |
Bavendam, T; Carlsson, M; Guan, Z; Kaplan, SA; Kreder, K; Rovner, ES; Sussman, DO | 1 |
Chiu, B; Chuang, YC; Chung, SD; Kuo, HC | 1 |
Aquilina, JW; Armstrong, RB; Chen, A; MacDiarmid, SA; Nitti, VW; Orman, C; Peters, KM | 1 |
Bavendam, T; Guan, Z; Kaplan, SA; Kraus, SR; Roehrborn, CG; Wang, JT | 1 |
Aizawa, N; Andersson, KE; Chen, Z; Igawa, Y; Imamura, T; Ishizuka, O; Nishizawa, O | 1 |
Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K | 1 |
Kadekawa, K; Miyazato, M; Mukouyama, H; Nishijima, S; Sugaya, K | 1 |
Becher, E; Gagnier, RP; Montorsi, F; Roehrborn, CG; Siami, P; Wilson, TH | 1 |
Yokoyama, O | 1 |
Gärtner, M; Havránek, O; Krhut, J; Nemec, D; Tvrdík, J | 1 |
Gotoh, M; Homma, Y; Kakizaki, H; Nishizawa, O; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 1 |
Fukuhara, S; Higashino, M; Hirai, T; Kanno, N; Kiuchi, H; Miura, H; Miyagawa, Y; Nakamura, Y; Nakayama, J; Nishimura, K; Nonomura, N; Okuda, H; Takao, T; Tsujimoto, Y; Tsujimura, A; Ueda, T; Yamamoto, K | 1 |
Akino, H; Aoki, Y; Ito, H; Nagase, K; Tanase, K; Yokoyama, O | 1 |
Gotoh, M | 1 |
Matsumoto, S; Ohtake, A; Okutsu, H; Sasamata, M; Sato, S; Suzuki, M; Uemura, H | 1 |
Cerqueira, JB; de Moraes, MO; Jamacaru, FV; Josino, IR; Nogueira, EA; Regadas, RP; Reges, R; Silva, LF; Sucupira, DG | 1 |
Arunkalaivanan, A; Sinha, D | 1 |
Bavendam, T; Carlsson, M; Guan, Z; Kaplan, SA; Roehrborn, CG; Rovner, ES | 1 |
Chugh, A; Malhotra, S; Mittra, S; Naruganahalli, KS | 1 |
Subramonian, K; Young, JG | 1 |
Amarshi, N; Bell, WA | 1 |
Abe, K; Egaway, S; Furuta, A; Ikemoto, I; Kishimoto, K; Kiyota, H; Kosugi, S; Shimomura, T; Shirai, H; Suzuki, Y; Takeuchi, H; Torii, S | 1 |
Bolodeoku, J; Cardozo, L; Robinson, D; Terpstra, G | 1 |
Akino, H; Aoki, Y; Ito, H; Miwa, Y; Oyama, N; Yokoyama, O | 1 |
Reviews
4 review(s) available for tamsulosin and Bladder, Overactive
Article | Year |
---|---|
The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
Topics: Acetanilides; Botulinum Toxins, Type A; Female; Humans; Male; Muscarinic Antagonists; Phosphodiesterase 5 Inhibitors; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
[Comprehensive pharmacologic management of overactive bladder].
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Combinations; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Sulfonamides; Tamsulosin; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive | 2017 |
[Clinical effectiveness and safety of combined therapy with alpha-blocker and an anticholinergic drug for bladder outlet obstruction with overactive bladder: a Meta-analysis of outcomes].
Topics: Adrenergic alpha-Antagonists; Cholinergic Antagonists; Drug Therapy, Combination; Humans; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2014 |
Trials
35 trial(s) available for tamsulosin and Bladder, Overactive
Article | Year |
---|---|
Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Single-Blind Method; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial.
Topics: Acetanilides; Adult; Drug Therapy, Combination; Humans; Middle Aged; Quality of Life; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Catheters; Urological Agents | 2020 |
Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
Topics: Acetanilides; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Single-Blind Method; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study.
Topics: Acetanilides; Age Factors; Aged; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Tamsulosin; Thiazoles; Urinary Bladder, Overactive | 2021 |
Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Urinary Bladder, Overactive | 2021 |
Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study.
Topics: Acetanilides; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Quality of Life; Single-Blind Method; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
An Exploratory Analysis of Tamsulosin for Overactive Bladder (OAB) in Men With Varying Voiding Symptom Burden.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cost of Illness; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Symptom Assessment; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Dutasteride; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Prostatic Hyperplasia; Quality of Life; Recovery of Function; Tamsulosin; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2021 |
Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical stud
Topics: Acetanilides; Drug Therapy, Combination; Humans; Male; Prostatic Hyperplasia; Quality of Life; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study)
Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Drug Therapy, Combination; Dutasteride; Humans; Imidazoles; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive | 2017 |
Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Greece; Humans; Male; Middle Aged; Muscarinic Antagonists; Organ Size; Pilot Projects; Prospective Studies; Prostate; Prostatic Hyperplasia; Severity of Illness Index; Solifenacin Succinate; Tamsulosin; Urinary Bladder, Overactive; Urination | 2018 |
A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Dutasteride; Humans; Imidazoles; Male; Prostatic Hyperplasia; Severity of Illness Index; Tamsulosin; Urinary Bladder, Overactive; Urological Agents | 2019 |
Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Imidazoles; Male; Middle Aged; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive | 2013 |
Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2014 |
[Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Topics: Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Chemistry, Pharmaceutical; Double-Blind Method; Drug Combinations; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Prostatic Hyperplasia; Solifenacin Succinate; Sulfonamides; Tablets; Tamsulosin; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Retention; Urodynamics; Urological Agents | 2015 |
Can we decide the optimal initial treatment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective, open-label study.
Topics: Aged; Decision Making; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostate; Quality of Life; Quinuclidines; Republic of Korea; Solifenacin Succinate; Sulfonamides; Symptom Assessment; Tamsulosin; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2014 |
A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Thiazoles; Urinary Bladder, Overactive | 2015 |
Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Solifenacin Succinate; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive; Urological Agents | 2015 |
Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
Topics: Adrenergic alpha-Antagonists; Aged; Cholinergic Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Solifenacin Succinate; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2017 |
[A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cross-Over Studies; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Solifenacin Succinate; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Quality of Life; Solifenacin Succinate; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.
Topics: Aged; Benzilates; Diagnostic Self Evaluation; Drug Therapy, Combination; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Nortropanes; Prostatic Hyperplasia; Self-Assessment; Solifenacin Succinate; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urinary Bladder, Overactive | 2017 |
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Prostatism; Quality of Life; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Prostatic Hyperplasia; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2008 |
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study.
Topics: Aged; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Quality of Life; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2008 |
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cohort Studies; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urination Disorders | 2008 |
Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.
Topics: Adrenergic alpha-Antagonists; Aged; Azasteroids; Double-Blind Method; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatism; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive; Urination | 2009 |
[Combination therapy with anticholinergics and alpha-blockers for the treatment of overactive bladder in female patients--pilot study].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Benzilates; Cholinergic Antagonists; Drug Therapy, Combination; Female; Humans; Middle Aged; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive; Urination | 2009 |
Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Prostatism; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2011 |
Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbolines; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Sulfonamides; Tadalafil; Tamsulosin; Urinary Bladder, Overactive; Urination; Urodynamics | 2013 |
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2006 |
A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Single-Blind Method; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2007 |
Other Studies
25 other study(ies) available for tamsulosin and Bladder, Overactive
Article | Year |
---|---|
Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related G
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Animals; Chemistry Techniques, Synthetic; Cystitis; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Imines; Molecular Docking Simulation; Mutagenesis, Site-Directed; Niacinamide; Rats; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Urinary Bladder; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2016 |
Editorial Comment.
Topics: Acetanilides; Humans; Male; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Urinary Bladder, Overactive | 2020 |
Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
Topics: Aged; Case-Control Studies; Cognition; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Mental Status and Dementia Tests; Middle Aged; Prostatic Hyperplasia; Quality of Life; Solifenacin Succinate; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive; Urological Agents | 2018 |
Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe.
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Europe; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Solifenacin Succinate; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Benzilates; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Nortropanes; Prostatic Hyperplasia; Solifenacin Succinate; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2015 |
Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
Topics: Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
Topics: Acetanilides; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Patient Safety; Prospective Studies; Sulfonamides; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents | 2016 |
Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Humans; Male; Middle Aged; Muscarinic Agonists; Organ Size; Phenylpropanolamine; Prostate; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Tract; Urination | 2009 |
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Topics: Adrenergic alpha-Antagonists; Adult; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Diuresis; Drug Therapy, Combination; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Agonists; Organ Size; Phenylpropanolamine; Prostate; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Retention | 2009 |
Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Muscarinic Agonists; Organ Size; Phenylpropanolamine; Prostate; Safety; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urologic Diseases | 2009 |
[Examination of the mechanism of ameliorating effect of alpha 1-blocker on storage symptoms associated with benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Female; Male; Prostatic Hyperplasia; Rabbits; Rats; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive | 2008 |
Re: Claus G. Roehrborn, Steven A. Kaplan, J. Stephen Jones, Joseph T. Wang, Tamara Bavendam, Zhonghong Guan. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of
Topics: Adrenergic alpha-Antagonists; Calcinosis; Humans; Inflammation; Male; Middle Aged; Prostate; Prostatic Diseases; Prostatitis; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive; Urologic Diseases | 2009 |
Role of alpha1-adrenergic receptors in detrusor overactivity induced by cold stress in conscious rats.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Body Temperature; Cold Temperature; Female; Indoles; Naphthalenes; Piperazines; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Urinary Bladder; Urinary Bladder, Overactive | 2009 |
Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder.
Topics: Adenosine Triphosphate; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Benzilates; Cholinergic Antagonists; Female; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive | 2009 |
Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Afferent Pathways; Animals; Benzhydryl Compounds; Brain; Cerebral Infarction; Cresols; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Excitatory Amino Acid Antagonists; Muscarinic Antagonists; Muscle Contraction; Nerve Fibers, Unmyelinated; Neuronal Plasticity; Phenylpropanolamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP1 Subtype; RNA, Messenger; Sulfonamides; Tamsulosin; Time Factors; Tolterodine Tartrate; Transcription, Genetic; Urinary Bladder; Urinary Bladder, Overactive | 2010 |
Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Male; Prostatic Hyperplasia; Severity of Illness Index; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive | 2011 |
Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Analysis of Variance; Animals; Disease Models, Animal; Diterpenes; Drug Therapy, Combination; Female; Infarction, Middle Cerebral Artery; Muscarinic Antagonists; Muscle Contraction; Organ Size; Quinuclidines; Rats; Rats, Sprague-Dawley; Solifenacin Succinate; Statistics, Nonparametric; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder; Urinary Bladder, Overactive | 2011 |
The mechanisms underlying α1-adrenoceptor antagonists and modulation of bladder function: an emerging role for changes in perfusion.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Female; Sulfonamides; Tamsulosin; Urinary Bladder; Urinary Bladder, Overactive | 2011 |
Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Disease Models, Animal; Female; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Sulfonamides; Tamsulosin; Urinary Bladder; Urinary Bladder, Overactive | 2011 |
Urethral syndrome: response to alpha-adrenergic blocking agents.
Topics: Adrenergic alpha-Antagonists; Adult; Depression; Female; Humans; Quinazolines; Remission Induction; Sulfonamides; Syndrome; Tamsulosin; Urinary Bladder, Overactive | 2006 |
Role of peripheral 5-HT1A receptors in detrusor over activity associated with partial bladder outlet obstruction in female rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-Antagonists; Animals; Dose-Response Relationship, Drug; Female; Hypertrophy; Piperazines; Pyridines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Adrenergic, alpha-1; Serotonin Antagonists; Serotonin Receptor Agonists; Sulfonamides; Tamsulosin; Up-Regulation; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2007 |
Treatment of men with lower urinary tract symptoms and overactive bladder.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2007 |
Treatment of men with lower urinary tract symptoms and overactive bladder.
Topics: Adrenergic Agonists; Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Drug Interactions; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2007 |
[A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
Topics: Administration, Intravesical; Administration, Topical; Adrenergic alpha-Antagonists; Animals; Atropine; Benzilates; Calcium Channel Blockers; Cholinergic Antagonists; Dinoprostone; Disease Models, Animal; Female; Injections, Intra-Arterial; Muscarinic Antagonists; Muscle Contraction; omega-Conotoxins; Oxytocics; Pressure; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamsulosin; Treatment Outcome; Urethra; Urinary Bladder; Urinary Bladder, Overactive; Verapamil | 2007 |